According to WHO 2021 brain tumor classification, we identified 14 patients with a molecular oligodendroglioma profile (IDH1 or 2 mutations, and 1p–19q chromosomal arm heterozygosity loss), of which 10 are WHO grade II and four WHO grade III. The gene discussed is IDH1; the disease is oligodendroglioma.